2 clips
a16z Podcast · Vasant Narasimhan
Novartis CEO explains how running multiple business units with different economics forced strategic capital misallocation. He describes the tough trade-offs between optimizing their pharmaceutical business versus investing in generics and devices, ultimately leading to a major corporate restructuring.
Novartis CEO Vasant Narasimhan explains how he transformed the pharmaceutical giant from a sprawling conglomerate into four focused companies through strategic spinoffs and divestitures. He details the spin-offs of Alcon and Sandoz, plus the sale of their Roche stake, which collectively unlocked nearly $180 billion in value.
